MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora no período 1998-2022
Hospital Miguel Servet
Zaragoza, EspañaPublicacións en colaboración con investigadores/as de Hospital Miguel Servet (5)
2019
-
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966
2006
-
Erratum: Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients (Annals Hematology (2006) 10.1007/s00277-005-0073-1)
Annals of Hematology
-
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol
Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183
-
Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients
Annals of Hematology, Vol. 85, Núm. 6, pp. 400-406